30 November 2020 - Late treatment study
The efficacy and safety of hydroxychloroquine in COVID19 patients : a multicenter national retrospective cohort
et al., medRxiv, doi:10.1101/2020.11.25.20234914 (Preprint)
Retrospective medical record analysis of acute care patients in Bahrain not showing a significant effect of HCQ.Confounding by indication is likely. Matching appears not to have matched for baseline severity - 17.5% of HCQ patients required oxygen while only 12.6% of control patients did.
|
risk of death, 16.7% lower, RR 0.83, p = 1.00, treatment 5 of 223 (2.2%), control 6 of 223 (2.7%), NNT 223, PSM.
|
|
risk of death/intubation, 75.0% higher, RR 1.75, p = 0.24, treatment 12 of 223 (5.4%), control 7 of 223 (3.1%), adjusted per study, PSM.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
Abdulrahman et al., 11/30/2020, retrospective, propensity score matching, Bahrain, Middle East, preprint, 9 authors.
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.